Literature DB >> 12386503

Use of vasopressor agents in critically ill patients.

John A Kellum1, Michael R Pinsky.   

Abstract

Distributive shock is a common problem in intensive care. Systemic hypotension is a medical emergency and will cause end-organ injury if not reversed. There are relatively few medications available to treat distributive shock. Catecholamines are most widely used for this indication and work by stimulating alpha- and/or beta-adrenergic receptors. Vasopressin and corticosteroids may have a role in reversing refractory shock and work primary through nonadrenergic mechanisms. Shock is difficult to define using hemodynamic criteria, because the same hemodynamic values can be normal in one patient, yet represent shock in another. Thus, the appropriate therapeutic endpoints for vasopressor therapy are not uniform for all patients. Similarly, the available evidence comparing vasopressor agents in terms of safety and efficacy is limited. When used at doses necessary to reverse distributive shock, less potent vasoconstrictors (eg, dopamine) do not appear to be safer than more potent ones (eg, norepinephrine) and do not appear to be as effective.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12386503     DOI: 10.1097/00075198-200206000-00007

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  11 in total

1.  The effects of increasing doses of noradrenaline on systemic and renal circulations in acute bacteraemic dogs.

Authors:  Zhi-Yong Peng; Lester A H Critchley; Benny S P Fok
Journal:  Intensive Care Med       Date:  2005-08-09       Impact factor: 17.440

Review 2.  The interface between monitoring and physiology at the bedside.

Authors:  Eliezer L Bose; Marilyn Hravnak; Michael R Pinsky
Journal:  Crit Care Clin       Date:  2015-01       Impact factor: 3.598

3.  Adrenergic receptor activation involves ATP release and feedback through purinergic receptors.

Authors:  Yuka Sumi; Tobias Woehrle; Yu Chen; Yongli Yao; Andrew Li; Wolfgang G Junger
Journal:  Am J Physiol Cell Physiol       Date:  2010-07-28       Impact factor: 4.249

4.  Acute microflow changes after stop and restart of intra-aortic balloon pump in cardiogenic shock.

Authors:  Christian Jung; Christoph Rödiger; Michael Fritzenwanger; Julia Schumm; Alexander Lauten; Hans R Figulla; Markus Ferrari
Journal:  Clin Res Cardiol       Date:  2009-04-15       Impact factor: 5.460

5.  Model-based prediction of the patient-specific response to adrenaline.

Authors:  J Geoffrey Chase; Christina Starfinger; Christopher E Hann; James A Revie; Dave Stevenson; Geoffrey M Shaw; Thomas Desaive
Journal:  Open Med Inform J       Date:  2010-07-29

Review 6.  Perioperative pharmacotherapy in patients with left ventricular assist devices.

Authors:  Nicholas C Dang; Yoshifumi Naka
Journal:  Drugs Aging       Date:  2004       Impact factor: 4.271

7.  The prevention of acute kidney injury an in-depth narrative review: Part 2: Drugs in the prevention of acute kidney injury.

Authors:  Norbert Lameire; Wim van Biesen; Eric Hoste; Raymond Vanholder
Journal:  NDT Plus       Date:  2009-02

8.  Sepsis carries a high mortality among hospitalised adults in Malawi in the era of antiretroviral therapy scale-up: a longitudinal cohort study.

Authors:  Peter I Waitt; Mavuto Mukaka; Patrick Goodson; Felanji D SimuKonda; Catriona J Waitt; Nick Feasey; Theresa J Allain; Paul Downie; Robert S Heyderman
Journal:  J Infect       Date:  2014-07-17       Impact factor: 6.072

Review 9.  Cerebrovascular Response to Phenylephrine in Traumatic Brain Injury: A Scoping Systematic Review of the Human and Animal Literature.

Authors:  Logan Froese; Joshua Dian; Alwyn Gomez; Bertram Unger; Frederick A Zeiler
Journal:  Neurotrauma Rep       Date:  2020-07-23

10.  The cerebrovascular response to norepinephrine: A scoping systematic review of the animal and human literature.

Authors:  Logan Froese; Joshua Dian; Alwyn Gomez; Bertram Unger; Frederick A Zeiler
Journal:  Pharmacol Res Perspect       Date:  2020-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.